DexCom (DXCM)
(Delayed Data from NSDQ)
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.22 -0.02 (-0.03%) 6:10 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.22 -0.02 (-0.03%) 6:10 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Zacks News
Will Core MedSurg Segment Aid Stryker's (SYK) Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) Q4 results are likely to be aided by its core MedSurg segment.
Here's Why Momentum Investors Will Love DexCom (DXCM)
by Zacks Equity Research
Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) top line in the fourth quarter of 2018 is likely to benefit from solid grow that the Instruments and Accessories segment.
Varian Medical (VAR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong overseas presence and product launches are likely to aid Varian Medical's (VAR) fiscal first-quarter results.
3 Medical Services Stocks to Buy in 2019: HQY, AMEH & OPGN
by Sreyoshi Mukherjee
Here we discuss three profitable Medical Services stocks as the industry booms.
AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife
by Zacks Equity Research
AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.
Here's Why Investors Should Bet on DexCom (DXCM) Right Now
by Zacks Equity Research
A solid guidance for 2018 and lucrative deals make DexCom (DXCM) a promising investment pick.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
DexCom Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
DexCom has been struggling lately, but the selling pressure may be coming to an end soon.
4 Healthcare Stocks That Popped More Than 100% in 2018
by Sapna Bagaria
Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.
Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look
by Zacks Equity Research
DexCom (DXCM) scores higher than Abiomed (ABMD) when it comes to current-year revenue projections and fundamentals.
4 Medical Device Stocks That More Than Doubled in 2018
by Sweta Jaiswal
Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.
5 Stocks That Popped More Than 100% in 2018 Defying All Odds
by Sreyoshi Mukherjee
Five solid picks that defied the problems confronting the U.S. economy.
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
What Falling Estimates & Price Mean for Alphatec Holdings (ATEC)
by Zacks Equity Research
Alphatec Holdings (ATEC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
DexCom (DXCM) Down 11.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Stocks to Gain as Fed Chair "Blinks" on Rates
by Swarup Gupta
Investors would now best prepare for sunnier days ahead, which make it imperative to pick select growth stocks.
Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel
by Zacks Equity Research
Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel
4 Profitable Stocks Boasting Amazingly High Net Income Ratio
by Zacks Equity Research
Profitability analysis is considered one of the best possible ways to assess the prospects of a company.
Here's Why Investors Should Bet on DexCom (DXCM) Right Now
by Zacks Equity Research
DexCom's (DXCM) focus on international markets is likely to lend it a competitive edge in the global MedTech space.
DexCom Amends Deal With Verily to Launch Advanced CGM by 2020
by Zacks Equity Research
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
Alphabet Halts Glucose Lens Work to Focus on Other Projects
by Zacks Equity Research
Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.
DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.